-- 英國聯合食品公司(ABF.L)週二確認了分拆零售和食品業務的計劃,同時公佈了受糖業疲軟等不利因素影響的上半年財報。 這家食品加工和零售公司計劃在2025年11月進行評估後,透過分拆的方式將其快時尚零售業務Primark與FoodCo業務分拆,預計將於2027年底完成。分拆後,兩家公司都將成為富時100指數成分股,但食品業務將保留ABF的名稱,現有股東將分別持有兩家公司的股份。 此次分拆預計將產生7,500萬英鎊的一次性分拆成本,而綜效損失預計將低於4,500萬英鎊。分拆完成後,ABF首席執行官喬治·韋斯頓將擔任FoodCo首席執行官,而伊恩·湯格將執掌Primark。 伯恩斯坦認為,Primark的分拆正如預期,是合理的策略舉措。 「從長遠來看,這是一個明智的決定,但根據我們的預測,短期內不會創造價值……總體而言,鑑於公司疲軟的基本面,儘管分拆業務是一個正確的決定,但我們預計其股價今天仍將走弱。」這家研究公司表示。 週二倫敦午盤交易中,股價下跌近3%。 ABF截至2026年2月28日的24週的歸屬於母公司股東的利潤為4.45億英鎊,低於截至2025年3月1日的24週的5.2億英鎊,這凸顯了公司面臨的困境。集團營收降至94.7億英鎊,以實際匯率計算與預期持平,但以固定匯率計算下降了2%,原因是ABF承擔了更高的前期成本並持續投資於未來的規模擴張。 由於新店開業“執行良好”,加上同店銷售額增長以及Primark在英國的市場份額提升,零售額增長了2%。但這些成長被歐洲消費者信心疲軟、美國食用油和烘焙原料需求下降、歐洲糖價下跌等因素所抵銷。 ABF維持了先前下調的全年業績預期,但糖業除外,目前預計糖業將全年虧損。儘管集團認為目前中東的成本壓力尚可控制,但警告稱,曠日持久的衝突可能會抑制非必需消費支出,對Primark的銷售前景構成風險。 「我們早就預料到本財年上半年會充滿挑戰,而我們的財務業績也印證了這一點。不過,我們仍然預期集團下半年的業績會有所改善。」韋斯頓表示。 「我們的食品雜貨和配料業務表現符合預期,但美國業務受到消費者需求疲軟的影響。我們的國際食品雜貨品牌實現了良好的銷售增長,並有望在下半年取得更強勁的盈利表現。糖業的業績低於預期,鑑於當前的市場狀況,我們對前景持更為謹慎的態度。」
Related Articles
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.